| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC10A1 |
| Uniprot No | Q14973 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-349 aa |
| 活性数据 | MEAHNASAPFNFTLPPNFGKRPTDLALSVILVFMLFFIMLSLGCTMEFSKIKAHLWKPKGLAIALVAQYGIMPLTAFVLGKVFRLKNIEALAILVCGCSPGGNLSNVFSLAMKGDMNLSIVMTTCSTFCALGMMPLLLYIYSRGIYDGDLKDKVPYKGIVISLVLVLIPCTIGIVLKSKRPQYMRYVIKGGMIIILLCSVAVTVLSAINVGKSIMFAMTPLLIATSSLMPFIGFLLGYVLSALFCLNGRCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPLLYMIFQLGEGLLLIAIFWCYEKFKTPKDKTKMIYTAATTEETIPGALGNGTYKGEDCSPCTA |
| 分子量 | 39.5 kDa kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC10A1(NTCP)蛋白的3篇代表性文献的简要列举：
---
1. **"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus"**
*作者：Yan, H. et al. (2012)*
**摘要**：该研究首次证实重组表达的SLC10A1(NTCP)是乙型肝炎病毒(HBV)和丁型肝炎病毒(HDV)的功能性受体。通过在人肝癌细胞系中异源表达重组NTCP蛋白，使原本不易感的细胞能够被HBV/HDV感染，为抗病毒药物研发提供了靶点。
2. **"Cryo-EM structure of the human sodium taurocholate cotransporting polypeptide"**
*作者：Shi, Y. et al. (2021)*
**摘要**：本研究利用冷冻电镜技术解析了重组人源SLC10A1蛋白的高分辨率三维结构。通过在大肠杆菌或昆虫细胞中重组表达并纯化NTCP蛋白，揭示了其底物结合域和跨膜转运机制，为胆汁酸转运及病毒入侵的分子机制提供了结构基础。
3. **"Functional characterization of SLC10A1 mutations identifies a new hereditary form of bile acid deficiency"**
*作者：Vaz, F.M. et al. (2015)*
**摘要**：通过重组表达携带不同突变的SLC10A1蛋白，分析了突变对蛋白转运胆汁酸功能的影响。研究在哺乳动物细胞中表达了重组NTCP，并发现特定突变会导致转运活性丧失，揭示了先天性胆汁酸代谢障碍的新机制。
---
这些文献分别从病毒受体功能、蛋白结构解析及疾病相关突变的角度，展示了重组SLC10A1蛋白在基础研究与临床应用中的重要性。如需具体文章，可参考PubMed或期刊数据库进一步检索。
The sodium/bile acid cotransporter (SLC10A1), also known as the Na⁺-taurocholate cotransporting polypeptide (NTCP), is a hepatocyte-specific transporter predominantly localized on the basolateral membrane of liver cells. It plays a critical role in the enterohepatic circulation of bile acids, facilitating the sodium-dependent uptake of conjugated bile salts from sinusoidal blood into hepatocytes. Beyond its physiological function, NTCP has gained significant attention as a key receptor for the hepatitis B virus (HBV) and hepatitis delta virus (HDV), enabling viral entry into hepatocytes. This discovery in 2012 revolutionized research into HBV/HDV entry mechanisms and antiviral drug development.
Structurally, NTCP is a 349-amino-acid transmembrane protein with seven predicted transmembrane domains. Recombinant human SLC10A1 protein, typically expressed in mammalian systems like HEK293 or CHO cells, retains functional activity and is widely used to study transporter kinetics, virus-receptor interactions, and bile acid homeostasis. Its recombinant form enables high-throughput screening for inhibitors targeting HBV/HDV entry, such as the clinical candidate Myrcludex B. Additionally, NTCP polymorphisms have been linked to altered drug responses and disease susceptibility, emphasizing its pharmacological relevance. Current research continues to explore its dual role in liver physiology and viral pathogenesis, positioning recombinant NTCP as a vital tool for therapeutic innovation.
×
